Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence

June 26, 2012, Virginia Commonwealth University

A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate cancer and lower the risk of recurrence with minimal radiation exposure to nearby healthy tissue and organs.

Recently published in the journal Brachytherapy, a novel treatment protocol designed by Michael Hagan, M.D., Ph.D., at VCU Massey Cancer Center, that combines intensity-modulated with high-dose rate (HDR) brachytherapy was tested on 26 prostate cancer patients. Intensity-modulated radiation therapy uses computer-controlled linear accelerators to modulate the intensity of an external to more accurately deliver radiation to tumors. HDR brachytherapy is an internal form of radiation therapy that uses small radioactive pellets implanted near the tumor.

"Recent studies have shown that both higher daily doses and higher total doses of radiation are better than standard doses in controlling prostate cancer, but these higher doses may be associated with higher rates of bladder and bowel complications," says the study's lead author Mitchell Anscher, M.D., Florence and Hyman Meyers Chair of and program co-leader of Radiation Biology and Oncology at VCU Massey Cancer Center. "Our study was designed to reduce radiation exposure to nearby healthy tissue and organs and we were pleased to find that this unique dosing schedule is safe and effective."

The toxicity of the therapy was relatively low and all 26 patients were able to complete treatment. The treatment required only one HDR brachytherapy implant, and all participants were treated as outpatients. After 4.5 years, none of the patients relapsed and the rate of long-term side effects was low.

"Our goal is to improve outcomes for our patients, so we are continually researching ways to reduce unnecessary exposure to healthy tissues and make treatments shorter and more manageable. We're hopeful our findings will lead to better tumor control rates and fewer complications for men with prostate cancer," says Anscher.

Moving forward, the researchers plan to continue exploring prostate cancer therapies using higher dose rates and shorter treatment times. The next step will likely be a four-treatment study utilizing stereotactic body radiosurgery, a technique popular with brain cancer that provides higher accuracy and requires fewer treatments by focusing high-powered X-rays on a very small area.

Explore further: Proton therapy effective prostate cancer treatment

More information: www.sciencedirect.com/science/ … ii/S1538472111003564

Related Stories

Proton therapy effective prostate cancer treatment

January 5, 2012
Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies published in the January issue of the International Journal of Radiation Oncology•Biology•Physics ...

IMRT cuts GI side effects from prostate cancer in half vs. 3D-CRT

June 1, 2011
Intensity modulated radiation therapy, a newer, more precise form of radiation therapy, causes fewer gastrointestinal side effects when combined with hormone therapy than using three-dimensional radiation therapy, according ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.